Carrie L. Melvin
EMD Serono, Inc. (United States) · 11 works · 429 citations · h-index 6
Top works
- Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor
- Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma
- Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC)
- Phase 1 first-in-human dose escalation study of cp-751,871, a specific monoclonal antibody against the insulin like growth factor 1 receptor
- Safety and tolerability of the anti-IGF-I receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in patients with advanced solid tumors
- 6508 ORAL CP-751, 871, an anti-IGF-IR antibody, in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC): A phase Ib/randomized phase II, non-comparative, open label trial
- Inhibition of the insulin like growth factor 1 receptor by a specific monoclonal antibody in multiple myeloma
- Phase 1 Dose Escalation Study of the Monoclonal Antibody Against the Insulin Like Growth Factor I Receptor CP-751,871 in Patients with Multiple Myeloma.
- An open-label, phase II study of tipifarnib for the treatment of HRAS mutant solid tumors, including squamous cell carcinomas of the head and neck.
- PRELIMINARY RESULTS FROM AN OPEN‐LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T‐CELL LYMPHOMA
- PD3-3-1: A phase Ib/randomized phase II, non-comparative, open label trial of paclitaxel and carboplatin with or without the anti-IGF-IR antibody CP-751,871 as first-line treatment for advanced non-small cell lung cancer (NSCLC)